NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

#  Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 7 December 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair) Present for all items
2. Dr Stephen Smith (Vice-chair) Items 4.1.3 to 4.2.2
3. Martin Bradley Present for all items
4. Dr Matthew Bradley Present for all items
5. Professor Sofia Dias Present for all items
6. Professor Rachel Elliott Present for all items
7. Christopher Herring Present for all items
8. Dr Andrew Hitchings Present for all items
9. Dr Robert Hodgson Present for all items
10. Dr Bernard Khoo Present for all items
11. Dr Ivan Koychev Present for all items
12. Dr Soo Fon Lim Present for all items
13. Dr Guy Makin Present for all items
14. Dr Philip Mallender Present for all items
15. Professor David Meads Present for all items
16. Giles Monnickendam Present for all items
17. Dr Malcolm Oswald Present for all items
18. Dr Rebecca Payne Present for all items
19. Carole Pitkeathley Present for all items
20. Dr Raju Reddy Present for all items
21. Professor John Watkins Present for all items

NICE staff (key players) present

Linda Landells, Associate Director Present for all items

Kate Moore, Project Manager Present for all items

Carl Prescott, Heath Technology Assessment Adviser Present for all items

Nigel Gumbleton, Heath Technology Assessment Analyst Present for all items

Maroulla Whiteley, Business Analyst, RIA Present for all items

Korin Knight, Senior Medical Editor Present for all items

Ella Fitzpatrick, Public Involvement Adviser, PIP Items 1 to 4.1.3

Lyn Davis, Coordinator, MIP Items 1 to 4.1.3

Gemma Smith, Coordinator, COT Present for all items

Mohammed Towhasir, Administrator, TA Present for all items

NICE staff (observers) present

Caron Jones, Heath Technology Assessment Adviser Present for all items

Ian Watson, Heath Technology Assessment Adviser - Methods Present for all items

Anne Murray Cota, Heath Technology Assessment Analyst Present for all items

Sarah Wilkes, Technical Analyst, Commercial Liaison team Present for all items

Catrin Austin, Technical Analyst, Methods, & Economics team Present for all items

Milena Wobbe, Technical Analyst, Managed Access team Present for all items

Georgina Fletcher, Media executive, Media Relations team Present for all items

Denise Moyo, Coordinator, COT Present for all items

External assessment group representatives present

Katherine Edwards, Liverpool Reviews and Implementation Group (LRIG) Items 1 to 4.1.3

James Mahon, Liverpool Reviews and Implementation Group (LRIG) Items 1 to 4.1.3

Clinical, Patient & NHS England experts present

Dr Emma Draser, Consultant Haematologist, clinical expert, nominated by Global Blood Therapeutics UK, Items 1 to 4.1.3

Layla Lawson, Patient Expert, nominated by The Essenelle Foundation, Items 1 to 4.1.3

Shubby Osoba, Patient expert, nominated by the Sickle Cell Society, Items 1 to 4.1.3

Dr Sanjeev Patel, Innovative Medicines Fund Clinical lead, NHS England, Present for all items

Professor Paul Telfer, Clinical Professor of Haemoglobin Disorders and Haematology, clinical expert, nominated by company, Global Blood Therapeutics UK, Items1 to 4.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Dr Megan John welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Dr Athanasios Saratzis and Professor Chris Parker.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 2 November 2022

### Appraisal of voxelotor for treating haemolytic anaemia in people with sickle cell disease [ID1403]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Global Blood Therapeutics.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor David Meads declared non-financial professional interests as the University of Leeds has received funding from BMS for research in an unrelated area. It was agreed his declaration would not prevent Professor Meads from participating in discussion on this appraisal.
* Committee member Dr Athanasios Saratzis declared personal interests in relation to research funded by industry in this area (management of anaemia in surgery). As a direct interest Dr Saratzis did not participate in discussion on this appraisal.
* Nominated clinical expert Dr Emma Drasar declared financial interests as she has received speaking and consultancy fees from GBT and Novartis. She is a PI for Celegene Believe Trial, SI for IMARA study and CI for Roche and ahs provided support & spoke for UK Thalassaemia Society and Sickle Cell Society. It was agreed that her declaration would not prevent Dr Drasar from providing expert advice to the committee.
* Nominated clinical expert Professor Paul Telfer declared financial interests as he has received research funding from GBT and Bluebird Bio for investigator-led studies on natural history of sickle cell disease in East London Sickle Newborn Cohort Study. He has also received honoraria for advisory board meetings organised by Novartis, Bluebird Bio, Vertex, Global Blood Therapeutics Direct and was the PI in commercial clinical studies sponsored by Novartis, Global Blood Therapeutics and Vertex. It was agreed that his declaration would not prevent Professor Telfer from providing expert advice to the committee.
* No further interests were declared for this appraisal.
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Professor David Meads, Professor John Watkins and Malcolm Oswald.
	1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10505>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Thursday 19 January 2022 and will start promptly at 09.30.